Prof Zhou Caicun (Shanghai Pulmonary Hospital, Tongji University School of Medicine Shanghai), Dr Ross Soo (National University Cancer Institute, Singapore) and a panel of Chinese oncologists were invited to have a discussion on Immunotherapy in 1L NSCLC. This webinar is led by Chinese Medicine Education Association, supported by Singapore Society of Oncology and sponsored by Roche.
Some of the topics covered during the webinar presentation and panel discussion includes
- Various treatments available in the market, including Impower150 as well as the recent FDA approved Impower110.
- Diagnostics for PDL1 testing
- Clinical interpretation of Impower110
- Strategy for Impower150 key subgroups
- Immunotherapy Strategy for different PDL1 subgroups